-
New Study on IPF-Related Cough
As a member of our Pulmonary Fibrosis News forums, you may have gotten an email this week about a new study being sponsored by Respivant Sciences, GmbH regarding an IPF-related cough. I can be the first one to speak to the amount of emails that come through some days, so this message may have been missed and I thought it would be beneficial to post the information on this platform as well. Here is the write-up that was distributed on behalf of the company, verbatim:
Almost all patients with Idiopathic Pulmonary Fibrosis (IPF) suffer from a dry, persistent chronic cough. This cough interrupts many aspects of daily life and significantly reduces quality of life in IPF patients. For example, affecting physical and social activities, exacerbating other respiratory conditions, causing sleep troubles, and limiting mobility.
We are making progress in the treatment of “general” chronic cough; however, we need more research studies to expedite the discovery of better cough treatment in patients with IPF.
You can help! Take action to advance IPF research and test a new potential treatment for IPF.
To find out whether a potential new drug may work to reduce the persistent cough in patients with IPF, you might consider joining the monARC ILD Patient Research Network.
*Please note: we are not endorsing the joining of the patient research network, or the participation in their study. This forum post was made for informational purposes only, and each members is welcome to join, or to refuse participation in this study based on their sole discretion.
Log in to reply.